 |
|
|
 |
|
Brain tumors may be classified as primary brain
tumors, defined as neoplasms originating within the brain itself,
and metastatic brain tumors, which are tumors that have spread to
the brain from elsewhere in the body. It was reported that the incidence
of primary brain tumors is 11~12 cases per 100,000 people annually.
In fact, the total number of patients in Japan with primary brain
tumors is approximately 13,000 to 14,000 people (General Rules for
Clinical and Pathological Studies on Brain Tumors, The Community
of Brain Tumor Registry of Japan, The Japanese Pathological Society,
second edition, 2002).
Glioblastoma is highly feared as the type of malignant tumor most
refractory to any treatment by current medical technologies. |
 |
We are developing a personalized peptide cancer
vaccine, ITK-1, which can be used for the treatment of advanced HRPC
and grade 4 malignant brain tumors.
The efficacy of these peptides to malignant brain tumors has already
been confirmed by exploratory clinical research carried out by academic
institutes including the Kurume University School of Medicine. |
We have already filed an IND application with the
PMDA and started Phase I trials of personalized peptide vaccines
for treatment of malignant brain tumors (glioblastoma).
Our target patients are HLA-A24(+) and are refractory to initial
treatment (radiation therapy or combination chemotherapy and radiation
therapy after surgery). We are administering personalized peptide
vaccines without any concomitant drugs to confirm the safety and
efficacy of the peptide vaccine. |
|
|
|
|
